Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that GLR2053 tablets independently developed by the company are undergoing phase I clinical trials in China, and recently successfully completed the administration of the first case to the test subjects.

A randomized, double-blind, parallel phase I clinical study was conducted to evaluate the safety, tolerability, pharmacokinetic and pharmacokinetic characteristics of GLR2053 tablets in healthy adult trial participants and food effects with single and multiple doses. As of the announcement date, no STAT6PROTAC products have been approved for listing worldwide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.